

# PEOPLE



ImaginAb (Los Angeles) has announced the appointment of **Benjamin Chen** (left) as CEO and **Joseph Limber** as chairman of the board of directors. Chen previously served as chairman and CEO of Immune Targeting Systems, and before that, was a managing director at life sciences merchant bank Burrill and Company. Limber spent nearly a decade with Prometheus Laboratories, serving as president, CEO and director. Previously, he was president and CEO of ACLARA Biosciences.

“Ben’s global biopharmaceutical leadership coupled with Joe’s extensive industry experience will be of tremendous value to ImaginAb as we progress our CD8 immune imaging program into the clinic this year,” said Abbie Celniker, former chairwoman of ImaginAb and current board member. “Joe’s knowledge of the industry and outstanding track record of introducing personalized medicine innovations that dramatically reshape patient care at Prometheus and other several highly successful companies makes him an excellent fit to serve as the chairman of our board of directors.”

Celgene (Summit, NJ, USA) has announced that president and COO **Mark Alles**, who has been with the company since 2004, will be its next CEO, succeeding **Bob Hugin**, who takes on the role of executive chairman. In addition, CFO and president of the company’s hematology and oncology franchise **Jackie Fouse** has been appointed president and COO; **Scott Smith**, currently president of the immunology and inflammation franchise, has been named chair of Celgene’s global management committee; and **Tom Daniel** has been appointed to be head of research and early development, a new position.

Personalized medicine company Epistem Holdings (Manchester, UK) has named **David Budd** CEO and director, effective the middle of April. Budd has over 20 years of international commercial and operational experience, most recently serving as general manager of Leica Biosystems Amsterdam. Ian Gilham will continue to act as interim CEO until Budd joins Epistem.

Aldeyra Therapeutics (Lexington, MA, USA) has announced the appointment of **David J. Clark** as chief medical officer. Clark has 18 years of clinical development experience with pharma and biotech companies, most recently as chief medical officer of Wilson Therapeutics.

**Alexander J. Denner** has been named chairman of the board of directors of ARIAD Pharmaceuticals (Cambridge, MA, USA). He is the chief investment officer and founding part-

ner of Sarissa Capital Management. He joined ARIAD’s board in February 2014.

Baxalta (Bannockburn, IL, USA) has announced that CEO **Ludwig Hantson** will leave once the company’s merger with Shire is finalized. Hantson previously served as president of Baxter International’s bioscience division and was named CEO when Baxalta was spun out in July 2015.

**Patrick (Pat) McBrayer** has been named president and CEO of ACell (Columbia, MD). He succeeds **Kyle Kerbawy**, who will remain as chairman of the board. McBrayer has more than 20 years of senior management experience in the healthcare industry. He was formerly president and CEO of AxioMed Spine Corp. and currently serves on the board of directors of Misonix.

Clinical-stage immunotherapy company ISA Pharmaceuticals (Leiden, the Netherlands) has announced the appointment of **Gerben Moolhuizen** as chief business development officer. He has over 20 years of pharma and biotech industry experience, most recently serving as general manager at OctoPlus. Previously, he held various roles in business development and product development at Pharming.

Cancer immunotherapy developer Gentecel (Labège, France) has named **Rémi Palmantier** CSO. Palmantier brings over 18 years of biotech and pharma industry experience, joining Gentecel from GlaxoSmithKline Vaccines where he was most recently senior director, R&D, for the global portfolio of immunotherapies for

chronic diseases. Formerly, he was head of cancer preclinical immunotherapies at GSK Biologicals (Canada).

**Matthew J. Pfeffer** has been named CEO of MannKind (Valencia, CA, USA), replacing company founder **Alfred Mann**, who had been serving as interim CEO since the resignation of Hakan Edstrom in November. Pfeffer will continue serving as CFO and join the company’s board of directors.



Ivenix (Amesbury, MA, USA) has announced the appointment of **Stuart A. Randle** (left) as CEO. Prior to joining Ivenix, Randle served as president and CEO of GI Dynamics. He

has over 20 years of experience in the life sciences industry, serving also as entrepreneur in residence at Advanced Technology Ventures, president and CEO at ACT Medical, and as a corporate officer at Allegiance Healthcare, where he was integral to the successful spin-off of Allegiance from Baxter International.

**Jeffrey Stoddard** has been appointed vice president, medical affairs at vaccine developer Novavax (Gaithersburg, MD, USA). He joins the company with more than 15 years of vaccine R&D experience, most recently serving as vice president, medical affairs and medical professional services at Alkermes.

**Dan Zabrowski** has been named to the board of directors of Exosome Diagnostics (Cambridge, MA, USA). He has 20 years of senior leadership experience at Hoffmann-La Roche, serving as president and director of Roche Diagnostics since 2012. From 2007 to 2012, he was head of Roche Pharma Partnering.

Axol Bioscience (Cambridge, UK) has appointed **Xianmin Zeng** CSO. Zeng has over 15 years of academic expertise in the development of stem cell technologies and its applications. She will continue in her current role as associate professor at the Buck Institute for Research on Aging.